InSilico Medicine Cayman TopCo (HKG:3696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
57.20
+6.90 (13.72%)
At close: Mar 27, 2026
Market Cap32.65B
Revenue (ttm)420.77M +77.8%
Net Income-348.07M
EPS-4.68
Shares Out570.75M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,146,420
Average Volume2,793,718
Open49.80
Previous Close50.30
Day's Range49.62 - 57.60
52-Week Range29.98 - 80.90
Betan/a
RSI50.74
Earnings DateMar 30, 2026

About HKG:3696

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is ... [Read more]

Sector Technology
Founded 2014
Country Cayman Islands
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3696
Full Company Profile

Financial Performance

In 2024, HKG:3696's revenue was $85.83 million, an increase of 67.71% compared to the previous year's $51.18 million. Losses were -$17.10 million, -91.92% less than in 2023.

Financial numbers in USD Financial Statements